Displaying drugs 10876 - 10900 of 11641 in total
Pexastimogene devacirepvec
Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma).
Investigational
Matched Description: … Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant …
JBPOS0101
JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
Investigational
Matched Description: … JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 …
Pecavaptan
Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients With Congestive Heart Failure).
Investigational
Matched Description: … Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients …
Uliledlimab
Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).
Investigational
Matched Description: … Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for …
Glutazumab
Glutazumab is a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein exerting anti-diabetic effects.
Investigational
Matched Description: … Glutazumab is a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein exerting anti-diabetic effects …
JNJ-17216498
JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.
Investigational
Matched Description: … JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment …
MRG-003
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
Matched Description: … MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated …
CEQ508
CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Investigational
Matched Description: … CEQ508 is a Live Attenuated E. …
Vamikibart
Vamikibart is under investigation in clinical trial NCT05642312 (A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema).
Investigational
Matched Description: … Vamikibart is under investigation in clinical trial NCT05642312 (A Study to Investigate Vamikibart in …
2,2':6',2''-Terpyridine Platinum(Ii)
2,2':6',2''-terpyridine Platinum(Ii) is a solid. Known drug targets of 2,2':6',2''-Terpyridine Platinum(Ii) include truncated transposase and autolysin.
Experimental
Matched Description: … 2,2':6',2''-terpyridine Platinum(Ii) is a solid. …
Veltuzumab
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Investigational
Matched Description: … Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials …
Sarafloxacin
Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Vet approved
Withdrawn
Matched Description: … Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories …
Prasinezumab
Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
Investigational
Matched Description: … Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of …
PF-04937319
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Description: … PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics …
BMS-791826
BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).
Investigational
Matched Description: … BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and …
PF-06650833
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Investigational
Matched Description: … 06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A …
RO-6870810
RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Description: … RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants …
Itolizumab
Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Investigational
Matched Description: … Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and …
PR006
PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene. It is being investigated for the treatment of dementia.
Investigational
Matched Description: … PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene …
OS2966
OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]
Investigational
Matched Description: … OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute …
F6-734
F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine pentaacetic acid (DTPA) (hMN-14 × m734).[A255217,A255222]
Investigational
Matched Description: … F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine …
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
Matched Description: … CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. …
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Matched Description: … MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. …
HOV-12020
HOV-12020 is a palm tocotrienols complex being investigated for the treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Investigational
Matched Description: … HOV-12020 is a palm tocotrienols complex being investigated for the treatment of cerebral autosomal-dominant …
Povorcitinib
Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)).
Investigational
Matched Description: … Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety …
Displaying drugs 10876 - 10900 of 11641 in total